At a glance
ClinicalIndex Comparison RecordN/ACompleted· 246 enrolled
Drug / intervention
PFDI-20 / PFIQ-7 questionnairesother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Prevalence of Pelvic Static Disorders in Women Treated for Localized Breast Cancer During Adjuvant Hormone Therapy.
Institut du Cancer de Montpellier - Val d'Aurelle·observational·Posted Aug 17, 2020·Updated Nov 4, 2021
In Brief
An observational study evaluating PFDI-20 / PFIQ-7 questionnaires for Breast Cancer. Completed, enrolled 246 participants across 1 site.
Detailed Summary
In this study, investigator propose to assess the prevalence of pelvic static disorders in women undergoing adjuvant hormone therapy for localized breast cancer and to assess the overall quality of life in these patients
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionFeb 2021
Study CompletionJul 2021
TodayJul 2026
First PostedAug 17, 2020
Enrollment StartSep 18, 2020
Primary CompletionFeb 12, 2021
Study CompletionJul 6, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.9 years ago
Interventions
PFDI-20 / PFIQ-7 questionnairesother
PFDI-20 / PFIQ-7 questionnaires (one shot)